Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease
- 18 August 2016
- journal article
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (1) , 85-90
Abstract
Purpose: To evaluate the effectiveness and safety of mycophenolate mofetil (MMF) as first‐line therapy combined with systemic corticosteroids in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada (VKH) disease.Methods: This prospective study included 38 patients (76 eyes). The main outcome measures were final visual acuity, corticosteroid‐sparing effect, progression to chronic recurrent granulomatous uveitis and development of complications, particularly ‘sunset glow fundus’.Results: The mean follow‐up period was 37.0 ± 29.3 (range 9–120 months). Visual acuity of 20/20 was achieved by 93.4% of the eyes. Corticosteroid‐sparing effect was achieved in all patients. The mean interval between starting treatment and tapering to 10 mg or less daily was 3.8 ± 1.3 months (range 3–7 months). Twenty‐two patients (57.9%) discontinued treatment without relapse of inflammation. The mean time observed off of treatment was 28.1 ± 19.6 months (range 1–60 months). None of the eyes progressed to chronic recurrent granulomatous uveitis. The ocular complications encountered were glaucoma in two eyes (2.6%) and cataract in five eyes (6.6%). None of the eyes developed ‘sunset glow fundus’, and none of the patients developed any systemic adverse events associated with the treatment.Conclusions: Use of MMF as first‐line therapy combined with systemic corticosteroids in patients with initial‐onset acute VKH disease prevents progression to chronic recurrent granulomatous inflammation and development of ‘sunset glow fundus’.Keywords
Funding Information
- King Saud University
This publication has 33 references indexed in Scilit:
- Myeloid-Related Protein-14/MRP-14/S100A9/Calgranulin B is Associated with Inflammation in Proliferative Diabetic RetinopathyOcular Immunology and Inflammation, 2018
- Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroidsActa Ophthalmologica, 2013
- The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada diseaseActa Ophthalmologica, 2012
- Mycophenolate mofetil monotherapy in the management of paediatric uveitisEye, 2011
- Comparison of the Clinical Efficacy of Two Different Immunosuppressive Regimens in Patients with Chronic Vogt-Koyanagi-Harada DiseaseOcular Immunology and Inflammation, 2010
- Mycophenolate Mofetil for Ocular InflammationAmerican Journal of Ophthalmology, 2010
- Concomitant Choroidal Inflammation during Anterior Segment Recurrence in Vogt-Koyanagi-Harada DiseaseAmerican Journal of Ophthalmology, 2008
- Vogt-Koyanagi-Harada disease in childrenEye, 2007
- Prognostic factors in Vogt-Koyanagi-Harada diseaseInternational Ophthalmology, 2007
- Spectrum of Vogt-Koyanagi-Harada disease in SingaporeInternational Ophthalmology, 2006